PUBLIC COMPANY
save$SPRBSPRUCE BIOSCIENCES, INC.
$SPRBSouth San Francisco, CA, USupdated 21d ago
community read0 votes
pipeline
1
marketed
0
phase 3
1
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 3
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2A Phase 2 Study to Evaluate the Safety, Efficacy and PK of Tildacerfont in Children Aged 2-17 Years With CAH
- phase2Study of SPR001 in Adults With Classic Congenital Adrenal Hyperplasia
- phase2A Study of Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary Syndrome and Elevated Adrenal Androgens
- phase2A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH
- phase2A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAH
- phase2Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia
Insider activity
source: SEC Form 4routine RSU / option mechanics (1)
- Mar 9, 26grantHooks Corwin Dale · Chief Commercial Officer11,000 sh
🐶 Hiring Signal
News
no news has mentioned this company yet
Data sources
last refreshed 13m ago
Found something off?
comments(0)
5-min edit window · permanent after that